Andrew Farquharson has been named director of technology transfer at MRC Technology (MRCT), effective September 1st. Mr. Farquharson will head up the team responsible for identifying, protecting and progressing life science research efforts.
 
Previously he held senior Intellectual Property roles in AstraZeneca UK and U.S., supporting R&D, business development and government affairs. Currently he runs a consultancy practice providing IP services to a range of life science and pharmaceutical clients and is appointed to the EU Commission’s Expert Group advising on the European Biotech Directive’s impact on patent law and R&D activity.
 
Dr. Dave Tapolczay, chief executive officer, MRC Technology, said, “Andrew’s extensive experience will support our charity’s work to ensure innovative life science research reaches its full potential and benefit a wider range of people. We look forward to having him on board!”